Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced that it has acquired Covagen AG, a privately held biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform. Cravath represented Cilag GmbH in connection with this transaction. Financial terms were not disclosed.

The Cravath team was led by partners Robert I. Townsend III and Damien R. Zoubek and included associates Andrew C. Elken and William D. Podurgiel on M&A matters; partner Eric W. Hilfers and associate Jarrett R. Hoffman on executive compensation and benefits matters; partner J. Leonard Teti II and associate Jay S. Gill on tax matters; partner David J. Kappos and associate Benjamin D. Landry on intellectual property matters; and partner Matthew Morreale on environmental matters. Matthew J. Bobby also worked on executive compensation and benefits matters.